Feb 02, 2017 12:00 pm UTC| Business
VIENNA, Austria, and KING OF PRUSSIA, Pa., Feb. 02, 2017 -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to...
Gaming and Leisure Properties, Inc. Announces Fourth Quarter and Full Year 2016 Results
Feb 02, 2017 12:00 pm UTC| Business
- Establishes 2017 First Quarter and Full Year Guidance -- Declares 2017 First Quarter Dividend of $0.62 per Common Share - WYOMISSING, Pa., Feb. 02, 2017 -- Gaming and Leisure Properties,Inc. (NASDAQ:GLPI) (the...
REGENXBIO to Participate in the SunTrust Robinson Humphrey 2017 Orphan Drug Day
Feb 02, 2017 12:00 pm UTC| Business
ROCKVILLE, Md., Feb. 02, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based...
MKS Instruments Reports Fourth Quarter and Full Year 2016 Financial Results
Feb 02, 2017 12:00 pm UTC| Business
Achieved record fourth quarter and full year semi revenueIncreased expected synergies from Newport Corporation acquisition from $35 million to $40 million Successful re-pricing of term loan in Q4 expected to save...
Aptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day
Feb 02, 2017 12:00 pm UTC| Business
SAN DIEGO and TORONTO, Feb. 02, 2017 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer,...
Beijing Rail Transit Control Center Selects Mitel to Communicate and Collaborate With Ease
Feb 02, 2017 12:00 pm UTC| Business
Beijing Rail Transit Control Center (TCC) oversees surveillance, emergency command and information sharing across rail networkNew communications solution covers 18 metro and light rail linesProvides staff with seamless...
Summit Therapeutics to Participate in February Investor Conferences
Feb 02, 2017 12:00 pm UTC| Business
OXFORD, United Kingdom, Feb. 02, 2017 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile...